Laddar populära aktier...
Arctic Bioscience – Minutes of the Extraordinary General Meeting
An Extraordinary General Meeting in Arctic Bioscience AS will be held Tuesday 19 November 2024 at 10:00 (CET), as a digital meeting.
Highlights Q3 2024: · The HeROPA 6-month read-out showed an effect close to the assumed effect level in the high dose active treatment ar...
Christer Valderhaug, CEO at Arctic Bioscience, has today bought 10,000 shares in Arctic Bioscience at an average price of NOK 1,72 per share...
Eggesbø Eiendom AS, a legal person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today so...
Daniele Mancinelli, CTO at Arctic Bioscience, has today bought 2,000 shares in Arctic Bioscience at an average price of NOK 2,40 per share.
Siglar AS, a legal person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today bought 20,0...
Hogne Hallaråker, CSO at Arctic Bioscience, has today bought 5,000 shares in Arctic Bioscience at an average price of NOK 2,50 per share.
Runhild Gammelsæter, Medical Director at Arctic Bioscience, has today bought 10,000 shares in Arctic Bioscience at an average price of NOK 2...
Gold Coast Nutrition, a legal person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today ...
With reference to yesterday’s stock exchange release regarding webcast to be hosted today at 12:00 CET to present the results from the HeROP...
With reference to stock exchange release regarding the results from the HeROPA clinical trial read-out.
All patients have passed 6 months of treatment in the HeROPA phase 2b clinical study, which compared HRO350 to placebo.
Arctic Bioscience are today presenting new research on cells at the EADV congress in Amsterdam.
Ronja Capital AS, a legal person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today tran...
Highlights H1 2024: · The HeROPA clinical trial fully recruited in January 2024 and proceeding as planned, de-risked by sufficient number...
Arctic Bioscience will publish its financial results for the first half year of 2024 on Thursday 29[th] of August, at 08:00 CET.
Nils Erik Bjørkedal, a person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has bought 10.
Sofie H. Valderhaug, a person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today bought ...
Arctic Bioscience are today presenting a new data on anti-inflammatory cellular functions of herring roe oil at the 9th European Workshop on...
Highlights Q1 2024: · The HeROPA clinical trial fully recruited in January 2024, and further development is proceeding as planned · A...
The Annual General Meeting of Arctic Bioscience AS was held Friday 26 April 2024 at 11:00 (CET).
Arctic Bioscience AS’ Annual General Meeting will be held Friday 26 April 2024 at 11:00 (CET), as a digital meeting.
Arctic Bioscience has today released its Annual Report 2023, including the Board of Directors report and financial statements.
The Board of Directors of Arctic Bioscience AS has resolved to extend the share option agreements for the following members of the managemen...
Highlights Q4 2023: · The HeROPA clinical trial fully recruited in January 2024 · Available liquidity end of 2023 of NOK 109,6 million ...
With reference to the stock exchange announcement from 17.
Arctic Bioscience will publish a Q4 2023 operational update and preliminary full year 2023 financial results on Friday 1[st] of March, at 08...
With reference to the stock exchange announcement from December 1[st] 2023 which reported more than 75% patients recruited to the phase IIb ...
With reference to the Q3 update from November 2[nd] 2023 which reported more than 50% recruited patients to the phase IIb clinical trial HeR...
Highlights Q3 2023: · Good progress in patient recruitment for the phase IIb HeROPA clinical trial, more than 50% recruited · New findi...
Highlights H1 2023: · The phase IIb HeROPA clinical trial for treatment of patients with mild-to-moderate psoriasis approved by Medicines...
Arctic Bioscience will publish its financial results for the half year 2023 on Tuesday 29[th] of August, at 08:00 CET.
Through the company’s primary bank, Arctic Bioscience has established a credit facility of NOK 30 million to support the nutra business grow...
Reference is made to the stock exchange release published by Arctic Bioscience 21 April 2023 regarding the Annual General Meeting’s approval...
Highlights Q1 2023: · The phase IIb HeROPA clinical trial approved in all the five European countries where the trial will be conducted ...
Reference is made to the stock exchange release regarding approval of share capital increase, published 21st April 2023.
Reference is made to the stock exchange release published by Arctic Bioscience earlier today 21 April 2023 regarding minutes from the Annual...
The Annual General Meeting of Arctic Bioscience AS was held Friday 21 April 2023 at 14:00 (CET).
Arctic Bioscience AS’ Annual General Meeting will be held Friday 21 April 2023 at 14:00 (CET), as a digital meeting.
Arctic Bioscience has today released its Annual Report 2022, including the Board of Directors report and financial statements.
Arctic Bioscience will publish its annual report 2022 on Wednesday 29 March 2023, at 08:00 CET.
Reference is made to the stock exchange release published by Arctic Bioscience 7th March 2023 regarding Board approval of share capital incr...
Reference is being made to the stock exchange release from January 12[th], 2023, where Arctic Bioscience announced that the Clinical Trial A...
Reference is made to the stock exchange release published by Arctic Bioscience 27th February 2023 regarding exercise of share options and co...
Daniele Mancinelli, CTO in Arctic Bioscience, has exercised 50.
Runhild Gammelsæter, Medical Director in Arctic Bioscience, has today bought 11,500 shares in Arctic Bioscience at an average price of NOK 1...
Per Christian Sæbø, COO in Arctic Bioscience, has today bought 4,500 shares in Arctic Bioscience at an average price of NOK 14.
Jone R. Slinning, CFO in Arctic Bioscience, has today bought 13,200 shares in Arctic Bioscience at an average price of NOK 14,3276 per share...
Daniele Mancinelli, CTO in Arctic Bioscience, has today bought 6.
Reference is made to stock exchange release from earlier today regarding acquisition of Arctic Algae AS.
Christer Valderhaug, CEO in Arctic Bioscience, has today bought 27.
Ronja Capital II AS, a legal person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today b...
Arctic Bioscience, a biotech company developing and commercializing pharmaceutical and nutraceutical products, today announces the acquisiti...
Highlights Q4 2022: · Positive development for psoriasis drug candidate HRO350 according to plan, with approval of the Clinical Trial App...
Reference is being made to the stock exchange release from January 12[th] 2023 where Arctic Bioscience announced that the Clinical Trial App...
Reference is being made to the stock exchange release from October 10th 2022, where Arctic Bioscience announced that Clinical Trial Applicat...
Highlights Q3 2022: · HRO350 development on track with CTA submitted start of October 2022 · First patient expected to be enrolled in Q...
Reference is being made to the stock exchange release from 3 October 2022 where Arctic Bioscience gave a status update related to the submis...
Reference is being made to the stock exchange release from 25 August 2022 regarding H1-2022 Reporting, where Arctic Bioscience announced tha...
With reference to the announcements on September 13.
Today, Arctic Bioscience, a biotech company developing, and commercializing nutraceutical and pharmaceutical products based on the unique pr...
Arctic Bioscience is pleased to invite investors, analysts, media and other stakeholders to a Capital Markets Update on 21 September 2022 in...
Highlights H1 2022 results:
Arctic Bioscience will publish its financial results for the half year 2022 on Thursday 25 August, at 08:00 CET.
Arctic Bioscience, a biotech company developing and commercializing nutraceutical and pharmaceutical products based on the unique properties...
The Annual General Meeting of Arctic Bioscience AS was held Thursday 5 May 2022 at 11:00 (CET).
Vartdal Holding AS, a legal person closely associated with a person discharging managerial responsibilities in Arctic Bioscience, has today ...
Arctic Bioscience AS’ Annual General Meeting will be held Thursday 5 May 2022 at 11:00 (CET), as a digital meeting.
Christer L. Valderhaug, CEO of Arctic Bioscience, has today bought 10,000 shares in Arctic Bioscience at an average price of NOK 16.
Christer L. Valderhaug, CEO of Arctic Bioscience, has today bought 10,000 shares in Arctic Bioscience at an average price of NOK 15.
Arctic Bioscience AS has today released its Annual Report 2021, including the Board of Directors report and financial statements.
Highlights · Successful private placement and IPO raising NOK 300 million in growth capital on Euronext Growth · Phase IIb clinical stu...
Arctic Bioscience AS will publish its financial results for the full year 2021 on Thursday April 7, 2022, at 08:00 CEST.
Reference is made to the stock exchange release published by Arctic Bioscience 23 February 2022 regarding Board approval of share capital in...
Arctic Bioscience has appointed Jone R. Slinning as the Company’s new CFO.
Arctic Bioscience AS, a biotechnology company developing and commercializing nutraceutical and pharmaceutical products based on the unique b...
Reference is made to the stock exchange notice on 13 January 2022 on the appointment of Christer Valderhaug as the new CEO in Arctic Bioscie...
Reference is made to the stock exchange release published by Arctic Bioscience 22 February 2022 regarding exercise of share options and corr...
Ole Arne Eiksund, outgoing CEO of Arctic Bioscience has exercised 76,180 share options at strike price NOK 9.
· Site feasibility for psoriasis phase IIb study with investigational medicinal product HRO350 complete · Project for new GMP manufactu...
Arctic Bioscience, a biotech company developing and commercializing pharmaceutical and nutraceutical products based on the unique properties...
Arctic Bioscience, a biotech company developing and commercializing nutraceutical and developing pharmaceutical products based on the unique...
· Psoriasis phase IIb study for HRO350 on track: site feasibility process ongoing in Europe as planned with positive response from sites ...
Arctic Bioscience, a biotech company with a pre-commercial pharmaceutical business and a commercial nutraceutical business, is pleased to an...
An extraordinary general meeting of Arctic Bioscience AS was held on 10 November 2021.
Arctic Bioscience AS - Notice of extraordinary general meeting – new date
Arctic Bioscience H1 2021 results: phase IIb study on track and revenue up 50% y/y
Arctic Bioscience AS will publish its financial results for the first half of 2021 on Thursday August 26, 2021, at 07:00 CEST.
PIR IV INVEST AS (“PIR IV”), an early stage investment SPV and major shareholder in Arctic Bioscience AS ("Arctic Bioscience"), today announ...
Arctic Bioscience announces today a grant of NOK 4.
Highlights · Raised NOK 300 million to fund pharmaceutical development program and new production facility · Listed at Euronext Growth ...
